The primary objective is to evaluate the safety, feasibility and tolerability of LIFU as an adjunct neuromodulatory treatment for MCI due to AD
Age
45–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Males and non-pregnant females, aged 45-85 years
Able and willing to give informed consent
Must meet the clinical criteria for MCI due to Alzheimer's disease
If receiving concurrent treatment with an AChEI and/or memantine, has been on a stable dose for at least 45 days
Able to communicate sensations during the LIFU procedure
You may not be if
Unable to undergo MR-imaging because of implanted pacemakers, medication pumps, aneurysm clips, metallic prostheses (including metal pins and rods, heart valves or cochlear implants), shrapnel fragments, permanent make-up or small metal fragments in the eye that welders and other metal workers may have, or if candidates are uncomfortable in small spaces (have claustrophobia).
Participants with more than 30% of the skull area traversed by the sonication pathway are covered by scars, scalp disorders (e.g., eczema), atrophy of the scalp, or implanted objects in the skull or the brain.
Participants with a history of seizure disorder.
Participants with clinically significant chronic pulmonary disorders e.g., severe emphysema, pulmonary vasculitis, or other causes of reduced pulmonary vascular cross-sectional area.
Participant does not speak English
Participant is pregnant or planning to be pregnant
